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Sodium-lithium countertransport and triglycerides in diabetic nephrop-
athy. Elevated erythrocyte sodium-lithium countertransport (SLC) ac-
tivity is an intermediate phenotype of essential hypertension among
Caucasians, and is controversially associated with nephropathy in Type
1 (insulin-dependent) diabetes. Hypertriglyceridemia is a frequent con-
comitant of elevated SLC in the general population, and may be found
in diabetic nephropathy. The present study was designed to investigate
the influence of kidney disease, serum triglycerides and blood pressure
on the intenndividual variability of SLC in Type 1 diabetes. SLC and
fasting major serum lipids were studied in 35 Type 1 diabetic patients
with persistently elevated urinary albumin excretion and in a group of
patients matched for age, sex and duration of diabetes, but with
normoalbuminuria. SLC was elevated in patients with clinical nephrop-
athy (N = 10; median: 420 jtmol lRBc1 hr') and in patients with
microalbuminuria (N = 25; median: 405 .tmol 1RBC hr I) compared
with normoalbuminuric patients (median: 296 rmol IRBC' hr'; P <
0.01 vs. both groups). Hypertriglyceridemia and hypercholesterolemia
were found only among patients with macroalbuminuria. Analysis of
covariance indicated that the association of elevated SLC with kidney
disease (P < 0.006 in all models) was largely independent of serum
triglycerides, but also of total cholesterol, insulin dose and measures of
glycemic control. Only diastolic blood pressure was positively associ-
ated with SLC (P < 0.02) independently from nephropathy (P < 0.005)
also after restricting analysis to the normoalbuminunc patients. Kidney
disease and raised blood pressure remain major concomitants of ele-
vated SLC in Type I diabetics.
The incidence pattern of clinical proteinuria in Type 1 (insu-
lin-dependent) diabetes mellitus and the observation of a family
clustering of this long-term complication strongly suggest that
the development of diabetic kidney disease may be explained
by the interaction between the metabolic abnormalities of
diabetes with a genetic background of susceptibility [1—3]. The
nature of the predispo sing genes is not known, but higher blood
pressure and prevalence of cardiovascular disease have been
reported in the parents of patients with diabetic nephropathy,
and this suggests that an inherited predisposition to essential
hypertension and/or to cardiovascular disease may be involved
in conferring the risk of diabetic renal disease [4—61. The
presence of elevated erythrocyte sodium-lithium countertrans-
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port activity (SLC) in Type 1 diabetic patients with kidney
disease initially appeared to provide further evidence in favor of
this hypothesis [5, 7, 8]. SLC is distributed in a bimodal pattern
in the general population [9, 10], where elevated activities find
a major concomitant in essential hypertension [9, 11—141. Fur-
thermore, segregation analyses among Caucasian pedigrees
have suggested that up to 80% of the inter-individual variability
in SLC can be explained by genetic effects, restricting to about
20% the relevance of environmental factors in the prediction of
SLC at statistical modeling of cross sectional data [15].
The initial assumption that the genetic component in SLC
may not be entirely blurred by the metabolic abnormalities of
diabetes [5, 7, 81 was directly supported by the finding of
elevated SLC in the parents of Type 1 diabetic patients with
nephropathy [16]. These findings were then questioned by a
number of studies, either failing to detect parental components
in the elevated SLC associated with diabetic nephropathy [17],
or just rejecting the presence of the phenomenon [18, 191.
Recent updates from three groups seem to consolidate the
existing contrasts [20—22], but no studies have directly ad-
dressed the possible reasons for the controversy to date, and
several questions remain unanswered.
In particular, hypertriglyceridemia is a known concomitant of
elevated SLC in the general population [23] and in selected
non-diabetic individuals [24—26]. Furthermore, serum triglycer-
ides may represent part of the environmental component in
SLC, as changes in serum triglycerides concentration may be
paralleled by changes in SLC [24, 27]. Hypertriglyceridemia
occurs frequently also in overt diabetic renal disease [28], and
the hypothesis that this factor may explain why only some
studies detected higher SLC in diabetic nephropathy has been
repeatedly postulated [18—20, 29]. Indeed, the measurement of
plasma lipids was neglected by all [5, 7, 16, 17, 21, 22] but one
[8] of the studies reporting elevated SLC in diabetic nephropa-
thy, where a positive association of SLC with serum triglycer-
ides was described in a subset of patients without clinical
proteinuria. Whether such a finding was independent of the
presence of microalbuminuria remained, however, unsolved.
Therefore, this study was designed to examine the contribu-
tion of kidney disease, major serum lipids concentration and
blood pressure to the inter-individual variability of SLC among
patients with Type 1 diabetes.
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Methods
Patient selection criteria
All Type 1 (insulin-dependent) diabetic patients we consid-
ered for this study attended the Diabetes Outpatient Clinic of
our Institute between 1987 and 1989, and were of Caucasian
origin. Forty-three patients with a urinary albumin excretion
rate (AER) persistently more than the current consensus
threshold for the diagnosis of microalbuminuria [30] in timed
overnight, nitrite dipstick-negative urine collections were thus
identified. After excluding two patients with persistent urinary
sediment abnormalities, 10 patients with clinical proteinuria and
25 with microalbuminuria accepted participation in the investi-
gation. These were matched for age, sex and duration of
diabetes to thirty-five out of a total number of 374 patients with
normoalbuminuria, without knowledge of other clinical fea-
tures. Such criteria were deemed appropriate to select normoal-
buminuric patients with a relatively low risk of developing
diabetic kidney disease. All patients gave their informed con-
sent to participate in the study, which was approved by our
local Ethical Committee.
Clinical measurements
Every patient attended a morning visit, when clinical features
were checked and a fasting blood sample was collected. Body
weight was obtained in light indoor clothing, and height was
measured without shoes. Body mass index (BMI) was calcu-
lated as usual, and expressed as kg/rn2. The currently pre-
scribed daily insulin dose was recorded. Resting blood pressure
(Korotkoff phases I/V) was measured once on the right arm by
ordinary mercury sphygmomanometry with approximation to
the nearest 5 mm Hg. The diagnosis of arterial hypertension
relied upon the finding of systolic blood pressure  160 mm Hg
and/or diastolic blood pressure 95 mm Hg and/or current
antihypertensive treatment. Mean blood pressure was calcu-
lated as the sum of diastolic blood pressure recordings with 1/3
pulse pressure. Eight patients were receiving anti-hypertensive
medication with one or two of a variety of drugs, including
angiotensin converting enzyme inhibitors, calcium channel
blockers, diuretics and beta blockers. One patient with overt
nephropathy was also receiving bezafibrate. All patients were
otherwise treated only with insulin, were studied in ordinary
glycemic control and were not suffering of any disease other
than long-term complications of diabetes. In particular, none
among our patients was known to suffer from thyroid disorders,
nor was any woman pregnant or taking oral contraceptives at
the time of the investigation. Anti-hypertensive treatment was
not withdrawn before the study, but the usual morning dose was
postponed until after the visit.
Sodium-lithium countertransport
SLC was measured according to the method originally de-
scribed by Canessa et al [11] with minor modifications, as
previously described [7]. By this method, the net exchange of
intracellular lithium for extracellular sodium is extrapolated by
measuring the difference in lithium effiux rate from lithium-
loaded erythrocytes into media without significant amounts of
sodium (passive lithium backdiffusion) and into media contain-
ing sodium at physiological concentration (passive backdiffu-
sion and Na/Li exchange). Lithium effiux was measured in
duplicate erythrocyte suspensions characterized by a low final
hematocrit (3 to 4%). Aliquots for the measurement of extra-
cellular lithium concentration were drawn at baseline (zero mm)
and after 15 and 30 minutes of incubation at 37°C. Lithium
concentration in the supernatants was measured by atomic ab-
sorption spectrophotometry (Perkin-Elmer 4000), with LiCl at
concentrations up to 0.050 mmollliter as the reference standard in
bidistiled water. Preliminary experiments showed that fresh effiux
buffers do not differ from distified water at the absorption wave-
length of lithium. Lithium effiux rates were obtained by calculating
the linear regression coefficients of lithium concentration upon
incubation time. After correcting for cell volume, these were
finally expressed as mol 1RBC' hr . Correlation coefficients
were higher than 0.98 in all of the experiments.
In our laboratory, observations in normotensive, normogly-
cemic, young members of Hospital Staff range from 115 to
536 pmol hr (N = 28; median: 249 mol
1RBC1 hr'), perhaps reflecting the lower component in the
bimodal distribution [9]. The average day to day intraindividual
coefficient of variation with this method approaches 11%, which
also accounts for short-term biological variability, and com-
pares with that described by other Laboratories using the same
technique [10, 11, 31].
Other measurements
Urinary albumin concentration was measured by a commer-
cial radioimmunoassay (Phadebas Albumin RIA, Pharmacia,
Uppsala, Sweden). Glycated hemoglobin (HbAIc) was mea-
sured by ion-exchange HPLC (Diamat, Bio-Rad, Richmond,
Virginia, USA; normal range: 4.0 to 6.0%). Routine clinical
chemistries were measured by enzymatic colorimetric tech-
niques on autoanalyzer (COBAS FARA II, Roche, Basel,
Switzerland). The diagnosis of hypertriglyceridemia was con-
sidered when serum triglycerides concentration was found
above the upper limit of normal in our laboratory (1.9 mmol/liter
= 170mg/dl). Serum total cholesterol concentration was judged
normal up to 5.17 mmol/liter (200 mg/dl) and frankly elevated
above the conservative threshold of 6.20 mmol/liter (240 mg/dl);
intermediate concentrations qualified as borderline hypercho-
lesterolemia.
Statistical analysis
Results were analyzed by a commercial software package
(JMP®, SAS Institute, Cary, North Carolina, USA) and are
presented as mean with standard deviation unless otherwise
indicated. Comparisons in normally distributed variables were
addressed by one-way analysis of variance, adjusting for mul-
tiple comparisons by Tukey-Kramer test. Rank transformation
was considered in context with all analyses including variables
that were found to deviate significantly from the normal distri-
bution. Univariate associations between continuous variables
were examined by linear models, and interactions with nominal
effects were addressed by analysis of covariance. Comparisons
in categorical variables were made by contingency table anal-
ysis. The null hypothesis was rejected below the conventional
(two-tailed) 5% level.
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Table 1. General clinical features of Type 1 diabetic patients with normal urinary albumin excretion, microalbuminuria and macroalbuminuria
Renal diagnosis Normoalbuminuria Microalbuminuria Macroalbuminuria P
Number 35 25 10 —
Age years 34.1 11.8 31.6 12.1 36.5 8.8 NS
Gender (M/F ratio) 1.5 1.7 1.5 NS
Duration of diabetes years 19.2 7.3 16.5 8.6 21.3 8.5 NS
Age at the onset of diabetes years 14.8 9.8 15.2 8.6 15.2 6.9 NS
Median AER g/min 4.5 42.4 547 —
(range) (2.0—15.7) (20.1—138.9) (213—1,773)
Serum creatinine pnol/liter
Body mass index kg/rn2
78 25
22.3 2.8
75 16
22.9 2.7
118 5l
23.5 2.6
0.0002
NS
Systolic blood pressure mm Hg 126.0 16.1 134.2 18.9 132.9 10.5 NS
Diastolic blood pressure mm Hg 79.5 8.1 83.0 10.6 84.3 8.5 NS
Mean blood pressure mm Hg 95.1 9.4 100.0 10,4 100.5 5.7 NS
Anti-hypertensive therapy (P/A) 1/34 1/24 6/4' 0.0001
Arterial hypertension % 8.6 28.0 60.0c 0.0021
Values are mean SD or median with range in parentheses. Abbreviations are: M, male; F, female; P, present; A, absent.
P, overall significance either at analysis of variance or at contingency table analysis, as appropriate.
a P < 0.01 vs. both non-proteinuric groups after adjusting for multiple comparisons by Tukey-Kramer test
b P < 0.005 vs. both non-proteinuric groups
P < 0.002 vs. patients with normoalbuminuria
Table 2. Metabolic features and major serum lipids concentration of Type I diabetic patients with normal urinary albumin excretion,
microalbuminuria and macroalbuminuria
Renal diagnosis Nonnoalbuminuria Microalbuminuria Macroalbuminuria P
Number 35 25 10 —
HbAIc % 8.4 1.8 8.6 1.2 9.6 2.4 NS
Blood glucose mmollliter 12.6 6.4 14.5 7.6 16.3 6.6 NS
Daily insulin dose Jul24 hr 43.6 12.5 48.7 13.8 40.7 8.7 NS
Median total cholesterol mmol/liter 4.96 4.67 5.42 NS
(range) (3.30—5.73) (2.80—6.35) (3.67—10.64)
Hypercholesterolemia (P/B/A) 0/13/22 1/8/16 4l2l4 0.0006
Median triglycerides mmol/liter 0.97 0.97 1.66 NS
(range)
Hypertriglyceridemia (P/A)
(0.26—1.96)
1/34
(0.28—3.18)
3/22
(0.56—5.40)
41&' 0.005
Values are mean SD or median with range in parentheses. Abbreviations are: P, present; B, borderline; A, absent.
P, overall significance either at analysis of variance or at contingency table analysis, as appropriate.
a P < 0.03 vs. both non-proteinuric groups
b p < 0.01 vs. patients with normoalbuminuria
Results
Clinical features of patients
The general clinical features of patients are shown in Table 1
according to the level of urinary albumin excretion. Age,
gender, duration of diabetes and age at the onset of diabetes
were comparably distributed in patients with microalbuminuria
and in patients with macroalbuminuria; in line with selection
criteria, these clinical features compared with those of normoal-
buminuric patients. Serum creatinine was normal (less than 133
j.mol/liter) in all patients without proteinuria; mean serum
creatinine was significantly elevated only among patients with
macroalbuminuria, although only three among them had clini-
cally increased levels. Body mass index was more than 28 kg/m2
only in two patients (one with normal AER and one with
microalbuminuria) but was otherwise normal and comparably
distributed in the three groups. Patients with microalbuminuria
showed a threefold prevalence of arterial hypertension com-
pared with the normoalbuminuric patients, but this difference
did not reach statistical significance, nor did the differences in
blood pressure recordings. Likewise, systolic and diastolic
blood pressure recordings were not significantly higher among
the macroalbuminuric patients. The prevalence of arterial hy-
pertension was, however, significantly elevated in patients with
macroalbuminuria, in association with a significantly higher
occurrence of cases receiving antihypertensive treatment.
The metabolic features of patients are displayed in Table 2.
No significant differences in HbAIc levels, fasting glycemia and
daily insulin dose appeared to characterize patients with raised
urinary albumin excretion compared with normoalbuminuric
controls. Fasting serum lipids were largely normal and compa-
rable in normoalbuminuric and microalbuminuric patients. Sig-
nificantly higher occurrence of hypercholesterolemia and hy-
pertriglyceridemia appeared to characterize only the patients
with macroalbuminurta. However, both total serum cholesterol
and triglycerides distributions significantly deviated from nor-
mality (Shapiro-Wilk test, P < 0.0001 for both variables) and
differences in their continuously distributed values failed to
reach significance after rank transformation.
Sodium-lithium countertransport activity
As SLC is known to follow a bimodal distribution in the
general population [9, 101, all statistical analyses conservatively
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Fig. 1. Scatterplot of eiythrocyte sodium-lithium countertransport ac-
tivity (SLC) in Type 1 diabetic patients with normoalbuminuria (AER <
20 g/min), microalbuminuria (AER = 20—200 /.Lg/min) and overt
nephropathy (AER > 200 g/min). Horizontal lines indicate the median
values. SLC was elevated in both groups with elevated urinary albumin
excretion (analysis of variance after rank-transformation: P = 0.0007;
also see Table 3). * P < 0.01 vs. patients with normoalbuminuria,
accounting for multiple comparisons by Tukey-Kramer test.
rested upon prior rank transformation. Mean SLC was 286
102 smol hC1 (median 296) in patients with normal
urinary albumin excretion. Significantly higher values compa-
rably characterized both patients with microalbuminuria (392
141 mol hr; median: 405; P < 0.01 after account-
ing for multiple comparisons) and patients with macroalbumin-
uria (463 185 jzmol 'RBC1 hr; median: 420; P < 0.01),
although relevant overlaps with the normoalbuminuric group
were manifest (Fig. 1). Simple regression analyses, as appro-
priately restricted to each subset of patients, failed to document
significant correlations of SLC with BMI, blood glucose,
HbAIc, daily insulin dose, total cholesterol and triglycerides.
To investigate the combined influence of renal diagnosis,
triglycerides, blood pressure and other clinical variables on
SLC, data were examined by analysis of covariance. This
method permits examination of how the interaction of one or
more continuously distributed variables with nominal effects,
such as the presence versus the absence of kidney disease, may
explain the interindividual variability of SLC.
Table 3 lists the levels of significance obtained in each model
where the effects of single covariates were compounded with
that of renal diagnosis. Each covariate was entered using the
native measurement units, but in the case of serum triglycer-
ides, total cholesterol and SLC, where rank transformed values
were used as previously justified. Only diastolic blood pressure
contributed to increase significantly the predictivity of the
whole model, independent of the effect of renal diagnosis.
Among the remaining study variables, duration of diabetes,
mean blood pressure, serum triglycerides concentration and
presence of hypertriglyceridemia appeared to associate with
some improvement in the overall model fit, but their partial
effect remained non-significant. In line with these observations,
the effect of renal diagnosis upon rank transformed SLC re-
mained highly significant in all models, and significantly ele-
vated values in SLC were found in both groups of patients with
elevated AER after adjusting for the effect of each covariate
(Table 3).
Larger models, where up to four covariates were added to
renal diagnosis, also failed to produce significant increases in
the overall model predictivity. After forcing HbAIc, daily
insulin dose, BMI and serum triglycerides into the model (r2
0.20, F = 3.7; P = 0.004), having microalbuminuria or macroal-
buminuria remained the only independent predictor of SLC (F
= 4.8, P = 0.012), while triglycerides still failed to reach a
significant effect (F = 3.6; P = 0.063). Findings were substan-
tially similar in other models, where these variables were
entered in smaller numbers but different combinations, when
blood glucose was entered instead of HbAIc, or when the
presence of hypertriglyceridemia, rather than the continuous
distribution of triglycerides, was considered.
The observation of a weak but independent association of
diastolic blood pressure with SLC suggested exploration of this
relationship in greater detail. Analysis of covariance models
was designed here with blood pressure as the dependent vari-
able, to allow the adjustment of SLC for the observed influence
of renal diagnosis. A small but significant proportion of the
interindividual variability in diastolic blood pressure was ex-
plained by SLC (F ratio = 5.3, P = 0.024; whole model r2 =
0.12; P = 0.043), but not by the presence of nephropathy. No
significant effects were observed upon systolic or mean blood
pressure. When the effects of age, gender, body mass index and
antihypertensive treatment were also taken into account, the
overall prediction of diastolic blood pressure was weakly in-
creased (r2 = 0.15), and only the effect of SLC was significant
(F = 4.34, P = 0.0415). This set of variables was more effective
in the prediction of systolic blood pressure (r2 =0.44) and mean
blood pressure (r2 = 0.28), most likely for a strong, independent
effect of age upon both (F = 38.2, P < 0.00001 and F 11.4, P
= 0.0013, respectively). In these models, SLC appeared to have
a significant effect upon mean blood pressure (F = 6.0; P =
0.017), but not systolic blood pressure (F = 3.7, P = 0.06).
Receiving antihypertensive treatment and renal diagnosis were
not shown to associate significantly with blood pressure in any
of these models, perhaps in line with an effective reduction in
blood pressure values among patients treated for hypertension.
To obviate the confounding effects of antihypertensive treat-
ment and renal abnormalities upon blood pressure in this set of
analyses, the effects of age, gender, body mass index and SLC
upon blood pressure were finally investigated by restricting
analysis to the subset of patients with normoalbuminuria, after
the exclusion of the single case receiving antihypertensive
treatment. A positive, independent and significant contribution
of SLC to arterial pressure was confirmed (Fig. 2, Table 4).
Insulin dose, blood lipids and measures of glycemic control all
failed to add and explain systemic arterial pressure among these
patients.
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Table 3. Independent analysis of covariance models, examining the contribution of clinical or metabolic covariate regressors to the effect of
renal diagnosis upon erythrocyte sodium-lithium countertransport activity (SLC) in 70 Type 1 diabetic patients with normoalbuminuria,
microalbuminuria and macroalbuminuria
Covariate
Whole
r2
model fit
P
Effects in model
Adjusted SLCaCovariate
P Renal diagnosisP Normoalbuminuria Microalbuminuria1' Macroalbuminuria"
None 0.19 0.0007 — 0.0007 26.8 3.1 42.2 3.7 49.0 5.8
Age 0.22 0.0008 NS 0.0006 27.0 3.1 41.6 3.7 49.9 5.8
Gender 0.20 0.0020 NS 0.0008 26.6 3.2 41.8 3.8 48.7 5.9
Duration of diabetes 0.23 0.0007 NS 0.0007 27.7 3.1 41.9 3.8 50.2 5.8
BMI 0.19 0.0032 NS 0.0015 26.9 3.2 42.0 3.9 48.7 6.0
Systolic blood pressure 0.20 0.0023 NS 0.0016 26.9 3.2 41.9 3.8 48.8 5.9
Diastolic blood pressure 0.26 0.0002 0.02 0.0031 27.7 3.1 41.3 3.6 47.4 5.7
Mean blood pressure 0.23 0.0066 NS 0.0006 27.7 3.2 41.1 3.7 47.8 5.8
Blood glucose 0.22 0.0011 NS 0.0014 26.3 3,3 41.9 3.7 48.1 5.9
HbAIc 0.20 0.0024 NS 0.0027 27.9 3.2 42.7 3.8 47.6 5.9
Daily insulin dose 0.19 0.0024 NS 0.0008 26.8 3.2 42.3 3.8 48.8 5.9
Cholesterol 0.21 0.0015 NS 0.0019 27.2 3.1 42.5 3.7 46.7 6.2
Hypercholesterolemia 0.20 0.0043 NS 0.0043 29.7 4.6 44.9 4.8 48.7 5.9
Triglycerides 0.23 0.0006 NS 0.0025 27.5 3.1 42.1 3.6 46.6 5.9
Hypertriglyceridemia 0.23 0.0007 NS 0.0058 32.6 4.6 46.8 4.6 50.2 5.8
a Values are the least square means s of the rank scores of SLC activity in each group of patients, as adjusted for the contribution of each
corresponding covariate
b p < 0.05 vs. normoalbuminuric patients in all models
100 200 300 400
Sodium-lithium countertransport, umol L8-1• hr1
Fig. 2. Effect of age, gender and BMI-adjusted sodium-lithium coun-
tertransport activity (SLC) upon mean blood pressure among 34 Type I
diabetic patients with normal urinary albumin excretion. To show usual
SLC measurement units, this scatterplot was obtained by entering
native SLC values into the model. The statistical effect of SLC (F = 7.2;
P = 0.012) was similar to that calculated after rank-transformation
(Table 4)
Discussion
This study supports previous evidence that SLC may be
elevated in patients with overt nephropathy [5, 7, 17] and that
comparably high SLC may already characterize patients with
microalbuminuria [8], the only subclinical abnormality of the
kidney presently known to reflect renal prognosis in Type 1
diabetes mellitus [32—34]. In line with previous observations,
Table 4. Multiple regression analyses exploring the effect of age,
gender, body mass index and erythrocyte sodium-lithium
countertransport activity (SLC) upon blood pressure in 34 Type 1
diabetic patients with normoalbuminuria and no treatment for
hypertension
Response
Who
r2
le model
fit
P
Effects model
Age
P
Gender
P
BMI
P
SLC
P
Systolic blood 0.40 0.0040 0.0021 NS 0.0423 0.0429
pressure
Diastolic blood 0.29 0.0358 NS NS NS 0.0188
pressure
Mean blood 0.40 0.0037 0.0118 NS 0.0199 0.0101
pressure
we also found that hypertriglyceridemia and hypercholesterol-1 emia may occur more often in patients with clinical nephropa-
500 thy [28], but not in microalbuminuria, where abnormalities in
serum lipids may be more subtle, and be found only by
examining their subfractions [28, 35, 36]. This pattern of results
seems to directly rule out the possibility that hyperlipidemia
may explain the finding of elevated SLC among our patients
with microalbuminuria, but corroborates the idea that both
abnormalities may coexist in patients with overt nephropathy
[18—20, 29]. However, statistical modeling indicated that ele-
vated SLC was significantly predicted by the presence of renal
disease, rather than by hyperlipidemia, also among these pa-
tients. Thus, although we cannot exclude that the association of
SLC with serum triglycerides may turn significant after exam-
ining more patients, diabetic kidney disease seems to predict
elevated SLC independent of serum major lipids concentra-
tions, suggesting that this phenomenon may not merely suffer a
major environmental influence from serum triglycerides, as
previously postulated [18—20, 29].
Differences in glycemic control and insulin dose are also
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unlikely to explain the association of nephropathy with elevated
SLC. Neither glycemia and glycated hemoglobin explained
SLC in our patients, nor in any other report where these
univariate correlations were investigated [5, 7, 8, 19]. This is
possibly restricting to less than 5% the univariate effect of
ordinary outpatient glycemic or HbAIc levels upon the interin-
dividual variability in SLC, in line with the hypothesis that
relatively worse glycemic control may be just an independent
concomitant of elevated SLC in patients with nephropathy [5,
21]. Although daily insulin dose was similar among our groups
of patients, this is a very indirect measure of the biodistribution
and bioavailability of insulin, and 24-hour profiles of serum-free
insulin levels have been reported to be more often elevated in
diabetic nephropathy [37]. Insulin is known to affect cellular
sodium metabolism, and careful studies of the activation kinet-
ics of SLC, as observed in truly saturating conditions, have
recently shown that insulin can acutely induce reductions in the
affinity of this exchanger for extracellular sodium [38]. There-
fore, although serum-free insulin concentrations were not mea-
sured in our patients, these mechanisms would be consistent
with a higher chance of underestimating SLC, ii anything,
among the patients with nephropathy.
Importantly, higher blood pressure appeared to reflect higher
SLC among our patients, independent of the concomitant
effects of attained age and BMI, but also independent of the
presence of nephropathy. While other studies either failed to
document any relationship between blood pressure and SLC in
Type I diabetic patients [19, 20, 39, 40], did not single out the
independent effect of increased urinary albumin excretion [41],
or described the presence of a positive association only among
the patients with diabetic kidney disease [8, 17], our finding is
largely consistent with that reported in a recent outpatient clinic
survey [22]. Furthermore, such an effect was still detectable
among our patients after restricting analysis to those with
normoalbuminuria, who were likely to represent a subset at
relatively low risk of developing nephropathy. This is in line
with the hypothesis that elevated SLC may reflect a higher risk
of developing arterial hypertension in Type I diabetic patients
who do not develop nephropathy [21], and further supports the
view that the metabolic alterations of Type 1 diabetes may not
totally confound the pathophysiology of this established con-
comitant of arterial hypertension in the general population.
Thus, taking together these observations, we would like to
speculate that the presence of kidney disease, eventually lead-
ing to hyperlipidemia, and raised blood pressure may find a
major concomitant in elevated SLC also among Type 1 diabetic
patients. Indeed, our findings seem to reflect those of cross
sectional studies in the general population, where a similar
independence in the statistical associations of blood pressure
and serum triglycerides with SLC was described by relying
upon similar laboratory techniques [12—14, 23, 27]. Although
the correlation of SLC with serum triglycerides appeared to be
restricted to the higher occurrence of elevated SLC and hyper-
triglyceridemia in overt nephropathy, we cannot exclude that
quantitative correlations may become manifest after studying
larger cohorts of patients. An indirect mechanism which may
explain a higher occurrence of raised serum triglycerides con-
centration among patients with elevated SLC could be repre-
sented by insulin-resistance. The reduction in peripheral sensi-
tivity to insulin action characterizing essential hypertension
[42], perhaps more often associated with elevated SLC [43],
may be relevant to explain susceptibility to hypertriglyceri-
demia in non-diabetic individuals. Recently, a similar associa-
tion of elevated SLC with some degree of insulin resistance and
raised serum triglycerides has been reported in Type 1 diabetic
patients without clinical proteinuria, albeit independent of
hypertension and microalbuminuria [44]. Alternatively, the
hypertriglyceridemia of overt diabetic renal disease may more
simply reflect the insulin-resistance of chronic renal disease
[45]. Finally, whether changes in the composition of the eryth-
rocyte membrane lipid bilayer, perhaps bound to excess lipid
peroxidation [19], may primarily relate with higher SLC inde-
pendent of the suggested effect of serum triglycerides [25], is
not known.
In conclusion, although we cannot rule out environmental
influences other than those considered in this study, raised
blood pressure and kidney disease remain major independent
concomitants of elevated SLC in Type I diabetes. Ordinary
glycemic and major serum lipids dysregulations do not seem
suitable candidates to explain these associations. Evidence of a
significant parental component remains the only other concom-
itant of SLC so far detected by others among Type 1 diabetic
patients [16, 17]. Thus, the hypothesis that the genetic deter-
minants of SLC may partly explain susceptibility to diabetic
kidney disease cannot be presently dismissed. Among the
several issues that remain to be answered, the adoption of
uniform laboratory techniques to measure Na/Li exchange may
represent the sine qua non to interpret controversial findings
[38]. The relevance of these observations to renal prognosis in
Type 1 diabetes remains to be established by prospective
studies.
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